Impact of Omalizumab Treatment on Quality of Life and Activity of Chronic Spontaneous Urticaria

Objective: Omalizumab treatment has shown promise in managing Chronic spontaneous urticaria (CSU). This study focuses on evaluating its effect on improving the quality of life and reducing CSU activity and severity in patients of different age groups. Materials and Methods: Conducted at Derince Training and Research Hospital, this observational study involved 50 CSU patients, categorized into adolescents (≤18years, n=15) and adults (>18years, n=35). Data were collected through clinical and demographic assessments, including Urticaria Activity Score (UAS), Urticaria Control Test (UCT), and Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) questionnaires, at the beginning and the third month of Omalizumab treatment. Results: Significant improvements were observed in UAS, UCT, and CU-Q2oL scores post-Omalizumab treatment, indicating reduced symptom severity and enhanced quality of life. The median UAS at the start was 35 (28-35); at the third month, 7 (0-7); median UCT at the start was 2 (1.25-3), at the third month 16 (13-16); median CU-Q2oL at the start was 70.5 (66-74), at the third month 23 (23-28); (p